Wireva

Tirzepatide Plus Eloralintide Yields 23% Weight Loss in Trial

Combining tirzepatide with the experimental drug eloralintide produced substantially greater weight loss than tirzepatide alone in a phase 2 trial of adults with type 2 diabetes, though side effects and dropout rates were higher.

Monitoring item. The full text is not distributed. Extract and source below.

Combining tirzepatide with the experimental drug eloralintide produced substantially greater weight loss than tirzepatide alone in a phase 2 trial of adults with type 2 diabetes, though side effects and dropout rates were higher.

Same event, other desks

Story file →